Skip to main content

Table 3 Baseline features of the participants

From: Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

Studies

Age (years)

Males (%)

Duration of DM (years)

HbA1c (%)

HBP (%)

CS (%)

 

DP/NDP

DP/NDP

DP/NDP

DP/NDP

DP/NDP

DP/NDP

Gantz2017

63.7/63.6

69.6/70.7

12.0/12.1

8.00/8.00

95.1/95.6

14.3/14.5

Green2015

Park2015

61.0/63.0

66.2/62.2

7.60/7.20

79.7/80.4

Scirica2013

65.1/65.0

66.6/67.3

10.3/10.3

8.00/8.00

81.2/82.4

Shih2016

74.5/74.5

46.2/46.2

8.70/8.70

90.9/90.9

Wang2015

66.0/65.9

64.0/63.7

75.1/75.9

White2013

61.0/61.0

67.7/68.0

7.10/7.30

8.00/8.00

82.5/83.6

13.0/14.3

  1. Abbreviations: DM Diabetes mellitus, HbA1c Glycated hemoglobin, HBP High blood pressure, CS Current smoker, DP Dipeptidyl peptidase 4 inhibitor group, NDP Non-dipeptidyl peptidase 4 inhibitor group